Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 12 855 M
EBIT 2017 3 812 M
Net income 2017 2 220 M
Debt 2017 12 078 M
Yield 2017 -
Sales 2018 13 314 M
EBIT 2018 4 102 M
Net income 2018 2 387 M
Debt 2018 10 052 M
Yield 2018 -
P/E ratio 2017 14,21
P/E ratio 2018 12,13
EV / Sales2017 2,65x
EV / Sales2018 2,40x
Capitalization 21 934 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
05/04Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/20 MYLAN : Response to Brian Elliott Piece in FT Entitled, “HIV/AIDS Drugs fo..
03/20 MYLAN : Receives Tentative Approval for "TLE400" Under PEPFAR
03/17 MYLAN : 5 Biotech Companies Set for Major Breakouts in 2017
03/15 Improved margins and Advair hopes lift drugmaker Hikma
03/13 MYLAN : Launches Generic Aromasin® Tablets
03/13 MYLAN NV : Blog Coverage Mylan Announces Launch of Generic Version of Pfizer's A..
03/13 MYLAN : Announces Global Settlement and License Agreements with Genentech and Ro..
03/10 MYLAN : to Present at Barclays Global Healthcare Conference
03/10 MYLAN : Launches Generic Pristiq® Tablets
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 51,7 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%21 934
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results